We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

CD47 Protein Products for Cancer & Cardiovascular Research

CD47 Protein Products for Cancer & Cardiovascular Research content piece image
Image Credit: AMSBIO
Read time: Less than a minute

AMSBIO has announced a new range of CD47-relevant productssuitable for rapid high throughput screening studies.

CD47, or Integrin associated protein (IAP), is a transmembrane protein that in humans is encoded by the CD47 gene. Studies have established that CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion and migration.  Furthermore, CD47 is known to be a key regulator of tissue homeostasis, and is also involved in a variety of diseases ranging from atherosclerosis to cancer. Given its significant role in pathogenesis of cancer and cardiovascular diseases, CD47 signaling has been heavily investigated for new targeted therapeutics.


The unique set of CD47-relevant products from AMSBIO includes human CD47 protein and multiple avi tag pre-biotinylated proteins. Derived from Human (HEK 293) cells, AMSBIO CD47 protein products demonstrate superb bioactivity, high detection sensitivity and authentic post translational modification and protein conformation. The new AMSBIO CD47 protein kits are supplied as pairs of products that can be easily adapted to ELISA, AlphaLISA™ and MSD platforms to facilitate rapid and easy screening of the neutralizing compound.